CTI Seeks ASP Payment For Zevalin; Medicare Cap Temporarily Lifted
This article was originally published in The Pink Sheet Daily
Executive Summary
Radioimmunotherapies shoud be reimbursed as biologic drugs, not radiopharmaceuticals, CTI CEO Bianco argues.